ArticleInflammopharmacology2025
Synaptamide regulates astroglial functional activity after cerebral cortex injury.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exercise-induced modulation of astrocyte in Alzheimer's disease: mechanisms and therapeutic implications.Frontiers in physiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Modern approaches to the treatment of traumatic brain injury (TBI) focus on alleviating life-threatening conditions. However, background glial activation processes occurring throughout the brain are often overlooked and may contribute to long-term damage and cognitive decline in patients with TBI. Currently, there is increasing evidence to support the influence of endogenous lipid messengers such as N-acylethanolamines fatty acids in neuropathologies. Synaptamide (N-docosahexaenoylethanolamine) plays an important role in brain repair after neurotrauma due to its significant anti-inflammatory, gliotropic and neuroprotective effects. The aim of this study was to investigate the processes of reactive astrogliosis occurring in two brain regions (cortex and thalamus) following cerebral cortex injury and synaptamide therapy (10 mg/kg/day, 7 days) in mice. Synaptamide was shown to reduce the expression of brain damage biomarkers in the blood, inhibit the development of reactive astrogliosis, and trigger the activation of anti-inflammatory A2 type reactive astrocytes, with the synthesis of the main brain neurotrophins (Clcf1, BDNF) in vitro and in vivo. The therapeutic efficacy of synaptamide demonstrated in this study makes it a promising drug for the treatment of TBI.
Indexed as
Identifiers
40617897What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.